Physician profile
Stephen Michael Auerbach
NPI 1811910649
$2,420.43
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $340 · 2021: $479 · 2022: $564 · 2023: $331 · 2024: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $520.74 | 2019-2024 | Xtandi, Myrbetriq |
| Pfizer INC. | $296.88 | 2019-2024 | |
| Progenics Pharmaceuticals, INC. | $264.07 | 2022 | |
| Myovant Sciences INC. | $246.72 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $171.50 | 2023-2024 | Orgovyx |
| Coloplast Corp | $169.17 | 2019-2021 | |
| Boston Scientific Corporation | $149.57 | 2023 | Ams 700 |
| Tolmar, INC. | $79.84 | 2024 | |
| Endo Pharmaceuticals INC. | $69.43 | 2021-2024 | Aveed, Xiaflex |
| Abbvie INC. | $67.59 | 2019-2024 | |
| Abbott Laboratories | $59.85 | 2024 | Proclaim |
| Travere Therapeutics, INC. | $45.16 | 2020 | |
| Blue Earth Diagnostics | $43.69 | 2021 | |
| Urovant Sciences INC | $39.62 | 2022 | |
| Hollister Incorporated | $27.04 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $26.79 | 2023 | Illuccix |
| Bard Access Systems, INC. | $24.63 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.78 | 2022 | |
| Myriad Genetic Laboratories, INC. | $19.94 | 2024 | Prolaris |
| Antares Pharma, INC. | $18.00 | 2024 | Xyosted |
| Abc Home Medical Supply, INC. | $15.66 | 2022 | |
| Metuchen Pharmaceuticals | $14.08 | 2019 | |
| Mission Pharmacal Company | $14.01 | 2019 | |
| Janssen Biotech, INC. | $13.67 | 2024 | Erleada |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Auerbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.